Literature DB >> 26171214

Analysis of circulating microRNAs during adjuvant chemotherapy in patients with luminal A breast cancer.

Ebru Esin Yoruker1, Fatma Aydoğan2, Uğur Gezer1, Pinar Saip2, Nejat Dalay1.   

Abstract

Breast cancer is a complex disease displaying different profiles involving genetic as well as epigenetic factors. MicroRNAs (miRNAs) are small, non-coding RNAs that regulate gene expression. Recent studies demonstrated that miRNAs may display great potential for the development of novel biomarkers and therapeutic targets. In the present study, the levels of miR-21 and miR-145 were analyzed in the peripheral blood of 52 patients with luminal A breast cancer. miRNA expression was determined in serum samples from matched pre- and post-treatment patients with breast cancer by quantitative polymerase chain reaction. There were no statistically significant differences in miR-145 and miR-21 levels between pre- and post-treatment samples. In addition, the miRNA levels were not found to be associated with the clinical parameters.

Entities:  

Keywords:  breast cancer; circulating microRNAs; serum samples

Year:  2015        PMID: 26171214      PMCID: PMC4487020          DOI: 10.3892/mco.2015.567

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  28 in total

1.  MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression.

Authors:  Bao Song; Chuanxi Wang; Jie Liu; Xingwu Wang; Liyan Lv; Ling Wei; Li Xie; Yan Zheng; Xianrang Song
Journal:  J Exp Clin Cancer Res       Date:  2010-03-27

2.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

3.  Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer.

Authors:  Hajime Shibuya; Hisae Iinuma; Ryu Shimada; Atsushi Horiuchi; Toshiaki Watanabe
Journal:  Oncology       Date:  2011-03-17       Impact factor: 2.935

4.  Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells.

Authors:  Lisa B Frankel; Nanna R Christoffersen; Anders Jacobsen; Morten Lindow; Anders Krogh; Anders H Lund
Journal:  J Biol Chem       Date:  2007-11-08       Impact factor: 5.157

5.  MicroRNA-21 targets tumor suppressor genes in invasion and metastasis.

Authors:  Shuomin Zhu; Hailong Wu; Fangting Wu; Daotai Nie; Shijie Sheng; Yin-Yuan Mo
Journal:  Cell Res       Date:  2008-03       Impact factor: 25.617

6.  Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.

Authors:  Li Ma; Julie Teruya-Feldstein; Robert A Weinberg
Journal:  Nature       Date:  2007-09-26       Impact factor: 49.962

7.  MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.

Authors:  Tyler E Miller; Kalpana Ghoshal; Bhuvaneswari Ramaswamy; Satavisha Roy; Jharna Datta; Charles L Shapiro; Samson Jacob; Sarmila Majumder
Journal:  J Biol Chem       Date:  2008-08-15       Impact factor: 5.157

8.  Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR‑145.

Authors:  Dong Ren; Min Wang; Wei Guo; Xiaohui Zhao; Xiang'an Tu; Shuai Huang; Xuenong Zou; Xinsheng Peng
Journal:  Int J Oncol       Date:  2013-02-12       Impact factor: 5.650

9.  Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma.

Authors:  Liqiang Qi; Joost Bart; Lu Ping Tan; Inge Platteel; Tineke van der Sluis; Sippie Huitema; Geert Harms; Li Fu; Harry Hollema; Anke van den Berg
Journal:  BMC Cancer       Date:  2009-05-28       Impact factor: 4.430

10.  Circulating microRNAs as specific biomarkers for breast cancer detection.

Authors:  Enders K O Ng; Rufina Li; Vivian Y Shin; Hong Chuan Jin; Candy P H Leung; Edmond S K Ma; Roberta Pang; Daniel Chua; Kent-Man Chu; W L Law; Simon Y K Law; Ronnie T P Poon; Ava Kwong
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

View more
  4 in total

Review 1.  Extracellular MicroRNA in liquid biopsy: applicability in cancer diagnosis and prevention.

Authors:  Alberto Izzotti; Stefano Carozzo; Alessandra Pulliero; Dinara Zhabayeva; Jean Louis Ravetti; Rakhmet Bersimbaev
Journal:  Am J Cancer Res       Date:  2016-07-01       Impact factor: 6.166

2.  MicroRNA-410-5p as a potential serum biomarker for the diagnosis of prostate cancer.

Authors:  Jiaqi Wang; Huamao Ye; Dandan Zhang; Yijun Hu; Xiya Yu; Long Wang; Changjing Zuo; Yongwei Yu; Guixia Xu; Shanrong Liu
Journal:  Cancer Cell Int       Date:  2016-02-19       Impact factor: 5.722

3.  Cancer-derived Circulating MicroRNAs Promote Tumor Angiogenesis by Entering Dendritic Cells to Degrade Highly Complementary MicroRNAs.

Authors:  Jiaqi Wang; Huamao Ye; Dandan Zhang; Kai Cheng; Yijun Hu; Xiya Yu; Lei Lu; Jingjing Hu; Changjing Zuo; Baohua Qian; Yongwei Yu; Shupeng Liu; Geng Liu; Chuanbin Mao; Shanrong Liu
Journal:  Theranostics       Date:  2017-03-24       Impact factor: 11.556

4.  Prognostic role of microRNAs in breast cancer: A systematic review.

Authors:  Eleni Zografos; Flora Zagouri; Despoina Kalapanida; Roubini Zakopoulou; Anastasios Kyriazoglou; Kleoniki Apostolidou; Maria Gazouli; Meletios-Athanasios Dimopoulos
Journal:  Oncotarget       Date:  2019-12-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.